The US District Court for New Jersey has ruled that Hospira has not infringed any laws in its pursuit of US Food and Drug Administration (FDA) approval for its generic version of Sanofi Aventis’ chemotherapy medication Eloxatin.

The company has tentative approval from the FDA for its generic version of the product and expects full approval shortly based on the ruling.

Hospira vice-president of speciality pharmaceuticals Joshua Gordon said that the company was very pleased with the ruling.

“The launch of Hospira’s oxaliplatin injection will provide a high-quality, lower-cost alternative to patients,” Gordon said.

The Hospira version of Eloxatin will be one of the first generic versions available in the US to come in “solution” form.